Proteomics International Laboratories Ltd. · ASX:PIQ
Proteomics International Laboratories — Shareholder Meeting (November 2025)
38 slides from Proteomics International Laboratories's shareholder meeting presentation, Nov 21, 2025
Slide 1: ASX Release: 2025 Annual General Meeting Chair's Address
ASX Release 21 November 2025 ASX code: PIQ 2025 Annual General Meeting Proteomics International Laboratories Ltd (Proteomics International; ASX: PIQ), a pioneer in precision diagnostics, is pleased to present the Chair’s Address and Company Presentation to be presented at the Company’s Annual Genera
Slide 2: About Proteomics International Laboratories
About Proteomics International Laboratories (PILL) (www.proteomicsinternational.com) Proteomics International (Perth, Western Australia) is a wholly owned subsidiary and trading name of PILL (ASX: PIQ), a medical technology company at the forefront of precision diagnostics and bio- analytical servic
Slide 3: Commercial Launch AGM Presentation
Proteomics International LABORATORIES LTD Commercial Launch AGM Presentation 21 November 2025 Dr. Richard Lipscombe Managing Director
Slide 4: Forward Looking Statements
ASX: PIQ Forward Looking Statements This Presentation is provided by Proteomics International Laboratories Ltd (Proteomics International, Proteomics, the Company, ASX: PIQ). You should not rely upon anything in this presentation and/or any information obtained from the Company, its Directors or thei
Slide 5: Proteomics International Key Highlights
ASX: PIQ Proteomics International Key Highlights Launching four first-in-class Large addressable markets Tests validated in large diagnostics in 2025 with significant unmet clinical studies medical needs Significant advantages over current OxiDx Standards-of-Care Funded to execute Consumer driven st
Slide 6: Corporate Overview
ASX: PIQ Corporate Financial and Corporate Overview • Strong Capital position ➢ $12M capital raise completed May 2025 comprising $4.5M Corporate Snapshot Institutional & Director placement + $7.5M oversubscribed SPP ASX code PIQ ➢ Funded to execute launch strategies Market Capitalisation (19 Nov 202
Slide 7: Problem & Solution: a suite of novel diagnostic tests
ASX: PIQ Problem & Solution: a suite Targeting major diseases which are currently detected late → existing outcomes are poor for of novel diagnostic tests patients & cost healthcare system billions of dollars • A novel and accurate blood test for predicting the onset of chronic kidney disease in typ
Slide 8: Market Opportunity
ASX: PIQ Market Large addressable unmet needs globally - targeting the US and Australian markets initially Opportunity 10.5% of the global adult population have diabetes 1 in 9 women have endometriosis 10-20% western populations have Gastroesophageal reflux disease (GERD) 537m adults globally endome
Slide 9: Disruptive Platform Technology
ASX: PIQ Disruptive Platform Promarker® platform technology drives a deep pipeline of novel precision diagnostic tests Technology Global potential in major markets • Promarker® engine develops novel intellectual property • Targeting new diagnostic tests in areas of significant unmet need • Uses prot
Slide 10: Product Development, Regulatory & Reimbursement
ASX: PIQ Product Development, Product rollouts at an advanced stage with well defined path forward Regulatory & Reimbursement Product status Next-generation PromarkerD immunoassay in clinic with comprehensive patent protection PromarkerEso mass spectrometry assay validated in three independent cohor
Slide 11: Business Model: utility of the Promarker tests
ASX: PIQ Business Model: utility Significant advantages over Standard-of-Care with the ability to drive clinical outcomes of the Promarker tests Standard-of-Care Biochemical blood or urine test Laparoscopy Endoscopy (SoC) Cost USD $34 - $59 Cost (average) USD $4,923 Cost (average) USD $2,750 • Does
Slide 12: Test Economics – Australia and United States
ASX: PIQ Test Economics – Highly attractive margins and first test now live in Australia and USA Australia and United States United States Target Launch Date 20-Jun-2025 Q4 CY25 Q3 CY25 Initial Capacity 84,000 p.a. 32,000 p.a. 32,000 p.a. Market Size (addressable patients) 32 million 66 million 67 m
Slide 13: Go-to-Market Strategy
ASX: PIQ Go-to-Market Clinician driven strategy supported by an on-line patient awareness campaign Strategy Direct to GPs & PCPs • Targeted and research driven awareness program • Integrated into Bp Premier Best Practice software (Aus) • Drive adoption of tests through GP & PCP clinics • 96% of US p
Slide 14: Market Launch: Ramp Up → Partnering
ASX: PIQ Market Launch: Drive near-term revenue with maximum optionality for strategic partnering Ramp Up → Partnering Focus on market Grow sales via Demonstrate market awareness and strategic partnerships adoption and sales launch of tests ✓ Developed suite of highly accurate, ✓ Engagement with GP
Slide 15: A Novel Blood Test for the Early Detection of Esophageal Cancer
A NOVEL BLOOD TEST FOR THE EARLY DETECTION OF ESOPHAGEAL CANCER PromarkerEso powered by Proteomics International
Slide 16: PromarkerEso: Esophageal Cancer
ASX: PIQ PromarkerEso: First-in-class blood test PromarkerEso in commercialisation phase Esophageal Cancer Clinical question – can a blood test distinguish between individuals who are: 1) healthy 2) esophageal adenocarcinoma (EAC) patients ➢ 66% of EAC patients report chronic acid reflux (GERD) ➢ bu
Slide 17: PromarkerEso: Esophageal Cancer
ASX: PIQ PromarkerEso: First-in-class blood test PromarkerEso in commercialisation phase Esophageal Cancer The latest clinical validation results for PromarkerEso were published in the peer-reviewed journal Proteomes in June. The study involved 259 serum samples across three independent patient coho
Slide 18: PromarkerEso: What are our Key Opinion Leaders saying?
ASX: PIQ PromarkerEso: What are our Key Opinion Leaders saying? My impression on Promarker®Eso market release “As a pathologist, I am keenly aware of the multitude of problems and limitations we have regarding detection of esophageal cancer and its precursors based on tissue analysis. Proteomic biom
Slide 19: A Novel Blood Test for the Early Detection of Endometriosis
A NOVEL BLOOD TEST FOR THE EARLY DETECTION OF ENDOMETRIOSIS
Slide 20: PromarkerEndo: Endometriosis
ASX: PIQ PromarkerEndo: First-in-class blood test PromarkerEndo commercialisation ready Endometriosis Clinical question – can a blood test distinguish between individuals who are: 1) healthy 2) symptomatic patients (pelvic pain but surgically-diagnosed absence of endometriosis) 3) endometriosis pati
Slide 21: PromarkerEndo: Endometriosis
ASX: PIQ PromarkerEndo: First-in-class blood test PromarkerEndo commercialisation ready Endometriosis The latest clinical validation results for PromarkerEndo were presented at the 16th World Congress on Endometriosis in May. The study involved over 700 samples. Figure: PromarkerEndo distribution of
Slide 22: Milestones: multiple value drivers achieved & ahead
Milestones: ASX: PIQ multiple value drivers achieved & ahead Q1 Q2 Q3 Q4 Milestone TARGET QTR FY25 FY26 FY26 FY26 FY26 Impact Commercial Australian lab certified for clinical testing ✓ Basis for all Promarker tests to be run clinically US Reference Lab established ✓ Key to first US sales and reimbur
Slide 23: Team: Board of Directors
ASX: PIQ Team: Highly experienced team with proven track record of delivering value for shareholders Board of Directors Dr James Williams PhD (Melbourne), MBA (UWA), BSc, Hons (Aberdeen), GAICD, Non-Executive Chair Experienced biotech leader and investor with roles spanning CEO, CTO, Director and Ch
Slide 24: Commercialisation Team
ASX: PIQ Commercialisation Dedicated industry focused team driving commercial adoption Team Phillip Prather Jacqueline Gray Chief Commercial Officer Chief Financial Officer & Head of Corporate Development Phillip brings extensive leadership in the global medical devices Jacqueline has held senior le
Slide 25: Investment Summary
ASX: PIQ Investment Summary • Commercialising x4 first-in-class blood tests for major diseases and conditions with significant unmet need • Ramp-up phase for PromarkerD & PromarkerEso with first sales already achieved • Commercial platform developed to drive awareness for each test in Australia and
Slide 26: Contact
ASX:PIQ ASX: PIQ Contact Dr Richard Lipscombe Dirk van Dissel Managing Director Corporate Advisory & Investor Relations T: +61 8 9389 1992 Candour Advisory E: enquiries@proteomicsinternational.com T: +61 408 326 367 www.proteomicsinternational.com E: dirk@candouradvisory.com.au 24
Slide 27: Supplemental – the Promarker suite of clinical diagnostic tests
Supplemental – the Promarker® suite of clinical diagnostic tests 25
Slide 28: Accreditations
ASX: PIQ The PILL Group holds one of the highest levels of accreditation Accreditations of any medical technology organisation globally Cutting edge laboratories with world leading accreditation: ❖ Australia ➢ ISO 15189: Clinical testing ➢ ISO 13485: Medical devices - Quality management systems (man
Slide 29: A Field Ready Blood Test for the Precise Measurement of Oxidative Stress
A FIELD READY BLOOD TEST FOR THE PRECISE MEASUREMENT OF OXIDATIVE STRESS
Slide 30: OxiDx: Oxidative Stress
ASX: PIQ OxiDx: Groundbreaking blood test nearing commercialisation Oxidative Stress What is Oxidative Stress? • Oxidative stress occurs when the body’s antioxidant defences are overwhelmed by an excess of toxic oxidants • Oxidative stress is implicated in over 70 World first results published: heal
Slide 31: OxiDx: Oxidative Stress
ASX: PIQ OxiDx: Proof of concept studies completed in high performance athletes and thoroughbred horses Oxidative Stress Figure: Heatmap depicting oxidative stress levels in Figure: Heatmap depicting oxidative stress levels in elite marathon runners. thoroughbred race horses. Colours depict thiol-ox
Slide 32: Promarker D
Promarker D PROACTIVELY CHANGING RENAL HEALTHCARE A simple blood test for predicting diabetic kidney disease
Slide 33: Problem and Solution – Diabetic Kidney Disease
ASX: PIQ Problem and Solution – Diabetic Kidney Disease Current standard-of-care diagnostics • Existing tests (known as eGFR and ACR) can only detect chronic kidney disease once it is already present • Current standard-of-care tests cannot predict the onset Roadblock of diabetic kidney disease The P
Slide 34: PromarkerD – Results & Intervention
PromarkerD – Results & Intervention ASX: PIQ How PromarkerD results are delivered LOW RISK MODERATE RISK HIGH RISK RISK SCORE % 0 10 20 100 Prognostic 16% indicates a moderate risk of decline in kidney function* Risk Score Intervention Testing Regimen Low Risk • Standard diabetes management Test Ann
Slide 35: PromarkerD: Clinical Utility & Decision Impact
ASX: PIQ PromarkerD: Launch strategy supported by engagement with KOLs and primary care physicians Clinical Utility & Decision Impact Published Research1 indicates physicians would use PromarkerD to inform patient treatment decisions • 96% of physicians were likely to use PromarkerD test scores for
Slide 36: PromarkerD: Diabetic Kidney Disease
PromarkerD: Diabetic Kidney Disease ASX: PIQ Intellectual Property Patents granted in all major jurisdictions - PromarkerD Patent family & Trademark covers 72% of the world’s diabetes patients CE Mark (EU) registration received for the PromarkerD Immunoassay IVD Regulatory US sales utilising Lab Dev
Slide 37: PromarkerD: What are our Key Opinion Leaders saying?
ASX: PIQ PromarkerD: What are our Key Opinion Leaders saying? My impression on Promarker®D market release "When kidney function is lost, it is lost forever. Identifying people at increased risk of developing impaired kidney function before this function is irreversibly gone is the best way to protec
Slide 38: Proteomics International
ASX: PIQ Proteomics International (Est’d 2001) Identity Proteomics International is a medical technology company specialising in predictive diagnostics and advanced analytical services using proteomics – the industrial scale study of the structure and function of proteins. Mission To improve the qua
Proteomics International Laboratories — Shareholder Meeting (November 2025) on 6ix